A young Egyptian scientist is besieging cancer... a global celebration of achievement
A young Egyptian scientist succeeded in making a discovery that represents a quantum leap in the face of cancer, which often develops without early detection.
And the scientist Cyril Shahdi concluded that cancer tumors secrete a liquid genetic material in the patient's blood, and through this material and its analysis, millions of information about the developments of the disease can be obtained.
Through this, it is possible to develop treatment plans for a cancerous tumor and determine the extent of its response to treatment or not, as well as a relief for patients from the misery of surgeries to take solid samples from tumors and replace that with the liquid sample discovered by the Egyptian scientist.
Shahdi, an assistant lecturer at the Faculty of Medicine, Cairo University, made this discovery by leading a large research team in the United States.
This team included researchers from Weill Cornell Medical College in New York, Cairo University, the Nevada Cancer Institute, the University of Washington and Harvard University.
The famous scientific journal Nature, through its oldest journal, the English Cancer Journal, celebrated this achievement and dedicated a special issue to it detailing its details on January 19.
According to the study published in "Nature", Cyril and his research team noticed that part of the genetic material of malignant tumors finds its way from the tumor to the blood vessels in the form of a liquid substance, and it has become easy to conduct genetic analyzes on the genetic material liquid in blood to help better understand the changes The genetic material that occurs during disease progression without exposing the patient to repeated sampling of the tumor, which requires complex surgical procedures that are not suitable for most patients.
The research team, which also includes among its members the Egyptian Bishoy Felts, conducted an extensive study to answer an important question for patients with bladder cancer, which is whether it is possible to use liquid genetic material to predict tumor response to treatment and understand the causes of disease resistance to treatment?
Cyril Shahdi told "Sky News Arabia" that his research team analyzed 182 liquid samples collected from 53 patients with advanced stages of bladder cancer while receiving treatment over a period of five years, and the liquid genetic material in those samples was analyzed using advanced technology, which enables us to From knowledge of genetic mutations and their quantity in the sample.
He added, "This study is one of the largest clinical studies on the follow-up of the fluid genetic material in the blood of patients with bladder cancer."
He continued, "The doctor always stands unable to tell the patient, who is in an advanced stage, whether there is a real benefit from treatment or not. Today we give the doctor and patient new hope and provide an important guideline for a better treatment plan."
According to Shahdi, the study proves that “the genetic analysis of the liquid genetic material in the blood predicts which patients will respond in an extended manner to treatment, and that genetic analysis can predict the development of the disease upon treatment.”
The study showed that the quantitative change of the liquid genetic material can predict treatment failure about three months before it appears using conventional CT scans, which gives the doctor ample time to change the treatment plan, according to Kirls Shahdi.
Follow our latest local and sports news and the latest political and economic developments via Google news